TOKYO, Jun 15 (Pulse News Wire) – Kringle Pharma,inc. (4884.T) announced today that it has entered into a collaborative research agreement with Keio University's Department of Orthopedic Surgery to develop acute-phase protein biomarkers for predicting natural recovery and evaluating treatment efficacy in patients with spinal cord injuries.
Under the collaboration, researchers will analyze samples collected during previous clinical trials involving acute-phase spinal cord injury patients. The aim is to enhance the precision of assessing therapeutic effects and predicting natural recovery, potentially leading to improved clinical trial analysis and more effective treatment strategies. The company noted that the impact on its performance from this initiative is expected to be minor. Spinal cord injuries affect approximately 6,000 people annually in Japan, with chronic patients bringing the total estimated patient count to 100,000 to 200,000 individuals.
HGF (Hepatocyte Growth Factor), which promotes cell proliferation and neuroprotection, is being studied for its potential in treating spinal cord injuries. Kringle Pharma is currently advancing late-stage development pipelines for spinal cord injuries and vocal cord scars, with additional phase III clinical trials planned. Kringle Pharma’s mission is to contribute to society by providing groundbreaking treatments for rare diseases through the development of HGF-based therapies. The company continues to push forward with its pipeline, aiming to create new value and improve public health through the social implementation of HGF.
🟢 Confidence: High AI-translated content.